Pharming Group

Profil de la société

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Description disponible en anglais.

Informations sur la société

Secteur

Santé

Industrie

Biotechnology

Pays

Pays-Bas

Siège

Darwinweg 24, 2333 CR, Leiden

Salariés

407

Cotation

PHARM · Euronext Amsterdam

Devise

EUR

ISIN

NL0010391025

Site web

pharming.com